GenMark Diagnostics, Inc. (NASDAQ:GNMK) is expected to report third quarter earnings results, after market close, on Wednesday 28th October 2020.
Analysts polled by Thomson Reuters anticipate third quarter loss of $ 0.06 per share.
Looking ahead, the full year loss are expected at $ 0.26 per share on the revenues of $ 164.19 million.
The Company Outlook
Revenue for 3Q20 are expected in a range of $ 42.60 million ~ $ 42.60 million
Full Year 2020 topline are forecasted in a range of$ 155.00 million ~ $ 165.00 million
Click Here For More Historical Outlooks Of GenMark Diagnostics, Inc.
Previous Quarter Performance
GenMark Diagnostics, Inc. reported loss for the second quarter of $ 0.07 per share, from the revenue of $ 40.09 million. The quarterly revenues extended 118.24 percent compared with the same quarter last year. The consensus estimates are loss of $ 0.09 per share from $ 32.74 million in revenue. The bottom line results beat street analysts by $ 0.02 or 22.22 percent, at the same time, top line results outshined analysts by $ 7.35 million or 22.45 percent.
Stock Performance
Shares of GenMark Diagnostics, Inc. traded up $ 0.33 or 2.89 percent on Tuesday, reaching $ 11.74 with volume of 797.00 thousand shares. GenMark Diagnostics, Inc. has traded high as $ 12.17 and has cracked $ 11.34 on the downward trend
According to the previous trading day, closing price of $ 11.74, representing a 239.58 % increase from the 52 week low of $ 3.36 and a 45.35 % decrease over the 52 week high of $ 20.88.
The company has a market capital of $ 834.38 million and is part of the Healthcare sector and Medical Devices industry.
Conference Call
GenMark Diagnostics, Inc. will be hosting a conference call at 4:30 PM eastern time on 28th October 2020, to discuss its 3Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.genmarkdx.com
GenMark Diagnostics, Inc., a molecular diagnostics company, develops and commercializes molecular tests based on its proprietary eSensor electrochemical detection technology. It provides ePlex instrument and respiratory pathogen panel, which integrates automated nucleic acid extraction and amplification with its eSensor detection technology to enable operators using ePlex system to place patient sample directly into its test cartridge and obtain results. The company offers XT-8 instrument, and related diagnostic and research tests, as well as certain custom manufactured reagents that enable reference laboratories and hospitals to support a range of molecular tests with a workstation and disposable test cartridges.
